Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 207.71M +81.1% |
| Revenue (ttm) | 17.56M +74.8% |
| Net Income | -147.39M |
| EPS | -14.10 |
| Shares Out | 15.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 260,492 |
| Open | 12.78 |
| Previous Close | 14.11 |
| Day's Range | 12.52 - 14.11 |
| 52-Week Range | 11.60 - 69.97 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+68.84%) |
| Earnings Date | May 11, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for TNXP stock is "Strong Buy" and the 12-month stock price target is $22.0.
News
Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year
Reports Q1 revenue $6.9M vs. $2.4M last year. “TONMYA is the first new fibromyalgia medicine in 15 years,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals (TNXP). “TONMYA…
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled
Tonix Pharmaceuticals secures commercial payer coverage for Tonmya
Tonix Pharmaceuticals (TNXP) announced an agreement with a leading group purchasing organization that provides coverage to approximately 35M U.S. commercial lives for Tonmya, a cyclobenzaprine HCl sub...
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine ...
Tonix Pharmaceuticals initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Tonix Pharmaceuticals (TNXP) with a Buy rating and $22 price target The firm cites Tonmya’s potential in fibromyalgia for the Buy rating. Consultants indicate Tonmya’s…
Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800
Tonix Pharmaceuticals (TNXP) announced presentation of Phase 1 data and plans for an adaptive Phase 2 field study of TNX-4800 for the prevention of Lyme disease in the U.S., at…
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreement Phase 2 field study expected to test a two-do...
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models TNX-1700 exh...
Tonix Pharmaceuticals publishes Tonmya study data findings
Tonix Pharmaceuticals (TNXP) announced the publication of a paper, “Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride, With Daily ...
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years
Tonix Pharmaceuticals presents TNX-4800 data, to initiate adaptive field study
Tonix Pharmaceuticals (TNXP) announced Phase 1 data of TNX-4800 was presented at the World Vaccine Congress Washington 2026. Tonix also announced its planned strategy for an adaptive Phase 2 field…
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and ...
Tonix Pharmaceuticals doses first patient in TNX-1900 study
Tonix Pharmaceuticals (TNXP) announced that the first participant has been dosed in a Phase 1 investigator-initiated study to evaluate the effect of TNX-1900 on trigeminal nerve-mediated vasodilation ...
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigem...
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announce...
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today an...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA t...
Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum
A new fibromyalgia therapy has launched with positive early adoption and broad prescriber engagement, supported by robust patient access and a dynamic commercial strategy. The pipeline includes a promising Lyme disease prevention antibody, and financial resources are strong.
Tonix Pharmaceuticals announces presentations on Tonmya
Tonix Pharmaceuticals (TNXP) announced two oral presentations on Tonmya, which was investigated as TNX-102 SL at the 8th International Congress on Controversies in Fibromyalgia held on March 9-10, 202...
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 ...
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain re...
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain re...
Tonix Pharmaceuticals publishes TNX-102 SL data in journal
Tonix Pharmaceuticals (TNXP) announced the publication of a paper in Clinical Pharmacology in Drug Development, the peer-reviewed journal of the American College of Clinical Pharmacology. Tonmya was i...
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ad...